LEADER

Psoriatic arthritis

TNF therapy in psoriatic arthritis and psoriasis

P Mease

Correspondence to:
Correspondence to:
Professor P Mease
Seattle Rheumatology Associates, 1101 Madison Street, Seattle, WA 98104, USA; pmease@nwlink.com

---

How and why does it work?

---

Keywords: psoriasis; psoriatic arthritis; anti-tumour necrosis factor

The first 150 words of the full text of this article appear below.

Specific inhibition of the cytokine tumour necrosis factor (TNF) has yielded dramatic improvements in the symptoms, signs, and quality of life of patients with chronic inflammatory diseases of Th1 phenotype such as rheumatoid arthritis (RA),^1–9 psoriatic arthritis (PsA),^10–14 ankylosing spondylitis,^15–17 psoriasis,^18–21 and Crohn’s disease.^22,23 The ability of anti-TNF therapy to inhibit disease progression in RA^5,6,24 and PsA^14,25 as evidenced by retardation of joint destruction by x ray analysis, has also been documented. Although these clinical results have been clearly demonstrated, our understanding of disease pathophysiology and demonstration of the specific cellular and immunohistochemical effects of new treatments continue to evolve. This review focuses on what has been recently learnt about the mechanism of treatment in PsA and psoriasis.

Psoriasis, occurring in approximately 1–3% of the population,^26,27 is a disease characterised by unsightly erythematous and indurated lesions, often with extensive silvery scale, which may cause significant impairment of . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• GUTIERREZ, M., FILIPPUCCI, E., BERTOLAZZI, C., GRASSI, W. (2009). Sonographic Monitoring of Psoriatic Plaque. The Journal of Rheumatology 36: 850-851 [Full Text]  
• Harrison, M J, Dixon, W G, Watson, K D, King, Y, Groves, R, Hyrich, K L, Symmons, D P M, and the British Society for Rheumatology Biologics, , on behalf of the BSRBR, (2009). Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor {alpha} therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 68: 209-215 [Abstract] [Full Text]  
• Moutsopoulos, N M, Katsifis, G E, Angelov, N, Leakan, R A, Sankar, V, Pillemer, S, Wahl, S M (2008). Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor {alpha} and systemic immune activation. Ann Rheum Dis 67: 1437-1443 [Abstract] [Full Text]  
• Voulgari, P V, Markatseli, T E, Exarchou, S A, Zioga, A, Drosos, A A (2008). Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 67: 567-570 [Abstract] [Full Text]  
• Kavanaugh, A, Krueger, G G, Beutler, A, Guzzo, C, Zhou, B, Dooley, L T, Mease, P J, Gladman, D D, de Vlam, K, Geusens, P P, Birbara, C, Halter, D G, Antoni, C, for the IMPACT 2 Study Group, (2007). Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66: 498-505 [Abstract] [Full Text]  
• van Kuijk, A W R, Reinders-Blankert, P, Smeets, T J M, Dijkmans, B A C, Tak, P P (2006). Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 65: 1551-1557 [Abstract] [Full Text]  
• Peek, R, Scott-Jupp, R, Strike, H, Clinch, J, Ramanan, A V (2006). Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis 65: 1259-1259 [Full Text]  
• Rahman, P, Siannis, F, Butt, C, Farewell, V, Peddle, L, Pellett, F, Gladman, D (2006). TNF{alpha} polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 65: 919-923 [Abstract] [Full Text]  
• Kary, S, Worm, M, Audring, H, Huscher, D, Renelt, M, Sorensen, H, Stander, E, Maass, U, Lee, H, Sterry, W, Burmester, G-R (2006). New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor {alpha} antagonists. Ann Rheum Dis 65: 405-407 [Abstract] [Full Text]  
• Mease, P J, Antoni, C E, Gladman, D D, Taylor, W J (2005). Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64: ii49-ii54 [Abstract] [Full Text]  
• Mease, P J, Antoni, C E (2005). Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64: ii78-ii82 [Abstract] [Full Text]